TransMedics Group, Inc. (NASDAQ:TMDX) Stake Lifted by New York State Common Retirement Fund

New York State Common Retirement Fund increased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 41.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,516 shares of the company’s stock after purchasing an additional 25,849 shares during the period. New York State Common Retirement Fund’s holdings in TransMedics Group were worth $6,908,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in TMDX. J.W. Cole Advisors Inc. bought a new position in shares of TransMedics Group during the 3rd quarter valued at about $929,000. Bank of New York Mellon Corp grew its position in TransMedics Group by 91.4% in the third quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock worth $41,615,000 after buying an additional 363,012 shares during the last quarter. Shariaportfolio Inc. bought a new position in shares of TransMedics Group in the third quarter valued at $470,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of TransMedics Group by 12.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,913 shares of the company’s stock valued at $378,000 after acquiring an additional 763 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of TransMedics Group by 12.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,940 shares of the company’s stock worth $818,000 after acquiring an additional 1,700 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 63,260 shares of the stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $108.54, for a total transaction of $6,866,240.40. Following the transaction, the insider now directly owns 9,792 shares of the company’s stock, valued at $1,062,823.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Edward M. Basile sold 7,157 shares of the business’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $86.38, for a total value of $618,221.66. Following the completion of the sale, the director now directly owns 8,350 shares in the company, valued at $721,273. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Tamer I. Khayal sold 63,260 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $108.54, for a total transaction of $6,866,240.40. Following the completion of the transaction, the insider now owns 9,792 shares in the company, valued at $1,062,823.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 236,378 shares of company stock valued at $23,633,449. Insiders own 7.00% of the company’s stock.

TransMedics Group Price Performance

Shares of TMDX stock opened at $127.99 on Friday. TransMedics Group, Inc. has a fifty-two week low of $36.42 and a fifty-two week high of $129.66. The stock’s 50-day moving average is $85.54 and its two-hundred day moving average is $76.85. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.40. The firm had revenue of $96.90 million for the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. The company’s revenue for the quarter was up 132.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.08) earnings per share. As a group, analysts anticipate that TransMedics Group, Inc. will post 0.54 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TMDX. Piper Sandler restated an “overweight” rating and set a $120.00 price objective (up previously from $95.00) on shares of TransMedics Group in a report on Wednesday. Morgan Stanley upped their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. Canaccord Genuity Group raised their price objective on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. increased their target price on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Oppenheimer raised their target price on TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a research report on Wednesday. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $119.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.